

1 **Title: Time series analysis of routine immunisation coverage during the COVID-19 pandemic in 2021**
2 **shows continued global decline and increases in Zero Dose children**

3 Author list: Beth Evans, Olivia Keiser, Laurent Kaiser, Thibaut Jombart

4
5 **Abstract**

6 Whilst it is now widely recognised that routine immunisation (RI) was disrupted by the COVID-19
7 pandemic in 2020 compared to previous immunisation performance, the extent of continued
8 interruptions in 2021 and/or rebounds to previous trends remains unclear, with sporadic surveys
9 reporting signs of immunisation system recovery at the end of 2020.

10 We modelled country-specific RI trends using validated estimates of national coverage from the World
11 Health Organisation and United Nation Children's Fund for over 160 countries, to project expected
12 diphtheria, tetanus, and pertussis-containing vaccine first-dose (DTP1), third-dose (DTP3) and measles-
13 containing vaccine first-dose (MCV1) coverage for 2021 based on pre-pandemic trends (from 2000-
14 2019).

15 We estimated a 3·6% (95%CI: [2·6%; 4·6%]) decline in global DTP3 coverage in 2021 compared to 2000-
16 2019 trends, from an expected 90·1% to a reported 86·5% across 164 reporting countries, and similar
17 results for DTP1 (2·8% decline; 95%CI: [2·0%; 3·6%]), and for MCV1 (3·8% decline; 95%CI: [4·8%; 2·7%]).
18 86·5% global coverage in 2021 represents a further decrease from that reported in 2020 and 2019, and
19 translates to a 16-year setback in RI coverage, i.e., 2005 levels. Hypothesised and early signals of
20 rebounds to pre-pandemic coverage were not seen in most countries. The Americas, Africa, and Asia
21 were the most impacted regions, with low- and middle-income countries the most affected income
22 groups.

23 The number of Zero Dose children also continued to increase in 2021. DTP1 coverage declined
24 worldwide from an expected 93.7% to a reported 90.9% (2.8% decline; 95%CI: [2.0%; 3.6%]) which
25 translates into an additional 3.4 million Zero Dose children on top of an expected 11.0 million (30.9%
26 increase) at the global level.

27 We hope this work will provide an objective baseline to inform future interventions and prioritisation
28 aiming to facilitate rebounds in coverage to previous levels and catch-up of growing populations of
29 under- and un-immunised children.

30

31 **Introduction**

32 It is now widely recognised that routine immunisation (RI) was disrupted globally during the start of the
33 COVID-19 pandemic and throughout 2020 [1–4]. Single-country studies, and literature reviews have
34 reported delays and interruptions in service delivery, decreases in attendance, and/or full suspension of
35 services during the pandemic, e.g., during periods of quarantine or implementation other non-
36 pharmaceutical interventions. Observational and modelling studies have evaluated the impact of
37 disruptions at the country-, regional-, and global-level in terms of coverage reduction, with estimates
38 ranging from 2% [5] to over 7% globally in 2020 [6]. We previously published an estimated 2.9% decline
39 for diphtheria, tetanus, and pertussis-containing vaccine third-dose (DTP3; 95% CI: 2.2%; 3.6%) and
40 similar declines for other key vaccine indicators [7]. Prior research has established associations between
41 lower vaccination coverage and outbreaks of vaccine preventable diseases (e.g., Measles outbreaks in
42 Zambia [8] and the United States of America [9]), highlighting the potential health implications of the
43 knock-on effects of the pandemic.

44 Whilst the evidence of RI disruptions in 2020 is now well documented, it remains unclear whether such
45 disruptions continued in 2021. Few papers have been published on 2021 coverage, with some

46 exceptions largely focussing on single countries (e.g., Brazil – [10]), and the grey literature hinting at a
47 potential decline in global coverage between 2020 and 2021 [11,12].

48 Here, we build on previously published methods to test and quantify the extent of RI disruption in 2021
49 compared to pre-pandemic trends. Reaching Zero Dose children (those that receive no vaccinations) is
50 crucial to reduce the most acute vaccine-preventable morbidity and mortality in infants. Therefore, we
51 translate modelled coverage disruptions into quantification of under- and un-immunised (i.e., Zero
52 Dose) children. We also investigate year-on-year trends within countries to identify rebounds and
53 continued declines, with the aim to facilitate future investigations of the key factors underpinning these
54 dynamics and focus efforts and resources to aid recovery.

55

56 **Materials and methods**

57 Data collection

58 Building on our previously published methodology to identify deviations from temporal trends in RI [7],
59 we investigated changes in RI coverage using three key indicators: diphtheria, tetanus, and pertussis-
60 containing vaccine first-dose (DTP1) and third-dose (DTP3) coverage, and measles-containing vaccine
61 first-dose (MCV1). To recap – DTP1 is typically administered at around six-weeks of age and is used as a
62 proxy for inequity to quantify Zero Dose children [13]; DTP3 is delivered to children of approximately
63 fourteen-weeks old and serves as a general marker for immunisation system performance, used by
64 national and global immunisation stakeholders; and MCV1 is recommended to be delivered at nine-
65 months of age and is often used as an additional indicator of health system performance.

66 We used coverage data published by the World Health Organisation and United Nation Children’s Fund
67 (UNICEF) Estimates of National Immunisation Coverage (WUENIC [14,15]) from 2000-2021 inclusive,

68 using the latest (July 2022) WUENIC data release [16]. It is noted that included within the latest WUENIC
69 release are retrospective revisions to previous-year (*i.e.*, pre-2021) coverage estimates for the
70 Democratic Republic of the Congo, Samoa, Tunisia, Guatemala, Philippines, and Cote d'Ivoire [16]. Such
71 revisions typically represent validation of population-level coverage surveys that replace previously
72 reported coverage levels for the current and some recent years. For this reason, we have updated
73 predictive modelling for expected coverage in 2020 using the latest WUENIC data rather than leveraging
74 previous results [7].

75 Population data was sourced from the United Nations World Population Prospects 2022 [17] release
76 (UNWPP 2022, including retrospective updates of 2021 populations). Income group classification was
77 taken from the World Bank's 2021 categorisation of countries [18].

78 Statistical analysis

79 We used Auto Regressive Integrated Moving Average (ARIMA) modelling [19] to capture temporal
80 trends in coverage for each country from 2000-2019 to forecast expected coverage in 2020 and 2021.
81 The inclusion of 2020 in the ARIMA model fitting to forecast coverage in 2021 was ruled out as many
82 countries showed sharp changes in point estimates of coverage that year. While this may result in wider
83 confidence intervals (CIs) for 2021 than 2020, results were essentially unchanged when also including
84 2020 in the model-fitting stage for countries which did not show sharp changes in 2020.

85 Prior to investigating global, regional, income group, and year-on-year differences between expected
86 and observed coverage, historic (pre-2020) and predicted time series were assessed, and countries were
87 removed from analyses for one of two reasons:

- 88 • **Prior knowledge:** Countries lacking recent WUENIC coverage updates: For 7 countries
89 (Cambodia, the Central African Republic, Haiti, Guinea, Lesotho, Somalia, and South Sudan),
90 WUENIC report an inability to update coverage estimates for successive years due to the

91 absence of additional information meeting their criteria, resulting in WUENIC coverage
92 estimates appearing as constant. In addition, countries with large geopolitical events known to
93 have affected immunisation were removed. This applied to Myanmar and the Democratic
94 People's Republic of Korea, where immunisation coverage reportedly fell over 60% between
95 2020 and 2021. Whilst some of these coverage declines may have been associated with the
96 pandemic, to be conservative we removed these countries for aggregate analyses.

97 • **Poor model fit:** Poor model fit was identified in countries where projected coverage in 2020 fell
98 outside either two standard deviations or six percentage points from WUENIC-reported 2019
99 coverage. Both of these scenarios were deemed to indicate programmatically unlikely changes
100 in coverage (either infeasible programmatic improvements or major disruptions). These
101 countries were removed to be conservative and not overly associate changes in coverage with
102 pandemic impact, where the explanation may be driven by poor model fitting (e.g., due to prior
103 year volatility, or skew from anomalous data points).

104 The list of countries, per vaccine dose, that were removed due to lack of reliability in assessing temporal
105 trends, are detailed in the Appendix (Section S4). We conducted a sensitivity analysis on aggregate,
106 regional and income group level analyses with no countries excluded – these are detailed in the
107 Appendix (Section S7).

108 Changes in coverage were measured as the difference between the reported and expected coverage for
109 a given year. Values are reported as percentages and these refer to percentage point changes. The
110 following analyses were completed for each vaccine dose:

111 • **Comparing expected versus reported coverage for 2021:** We conducted *t-tests* of reported
112 vaccination coverage against the null hypothesis of the absence of change in trends from prior
113 years for 2021 at the global level, and by region and income group – to investigate the existence

114 of RI impact in 2021. We then investigate regional and income group-level heterogeneities,
115 using linear models with coverage changes as a response variable and ANOVA using the
116 corresponding categorisation of countries. Differences between individual countries were
117 assessed by comparing the 95% CIs of the linear models' coefficients.

118 • **Calculating additional missed immunisations:** We calculated the additional number of missed
119 immunisations by combining the estimated changes in coverage (including estimates of low- and
120 high-bounds using 95% CIs) with surviving infant population estimates reported in the UNWPP
121 2022 dataset. These results indicate the number of additional unvaccinated children per country
122 that would have been reached based on previous immunisation trends.

123 • **Trends in coverage from 2020 to 2021:** We investigated absolute changes in coverage between
124 2020 and 2021 per country to quantify the extent of recovery and continued coverage declines.
125 We tested whether trends in 2020 were associated with trends in 2021, by conducting Fisher's
126 Exact tests on the relevant contingency table.

127 All analyses were conducted using R, version 4.1.2 [20] and can be reproduced using a publicly available
128 *reportfactory* including required data (all publicly available) and scripts [21].

129

130 **Results**

131 2021 coverage

132 After removing countries further analyses were conducted on: 164 countries for DTP3, 168 countries for
133 DTP1, and 160 countries for MCV1. Examples of coverage trends for the largest countries included are
134 shown in **Figure 1** for each vaccine dose. Similar trends can be seen within countries across different
135 vaccine doses (with DTP1 and DTP3 being more similar than MCV1 coverage trends), and large
136 differences between countries.

137 *Insert figure 1*

138 **Figure 1 – Expected and reported 2020 and 2021 vaccine coverage for DTP1, DTP3, and MCV1:** example of five countries with
139 largest populations in completed datasets. These graphs show WUENIC-reported coverage data (black dots) from 2000 to 2021
140 inclusive, and the corresponding ARIMA predictions and the associated 95% CIs (red bars) for 2020 and 2021.

141 The exact magnitude of coverage change remained hard to assess for two-thirds of countries due to
142 uncertainties in model predictions (**Figure 2**) – however global trends remained clearly apparent. In
143 2021, eight more countries showed statistical evidence ($p < 0.05$) of changes in coverage compared to
144 2020 (for DTP3: $n = 39$ in 2021 and $n = 31$ in 2020. In 2020 all 39 countries had coverage declines below
145 CIs and in 2021 30/31 countries had coverage declines below CIs, and 1 – Namibia - increased coverage
146 above expected CIs). Conducting a *t-test* on within-country differences in coverage between years
147 further confirmed that coverage declines were greater in 2021 than in 2020 ($df = 160$, $t = -3.31$, $p =$
148 0.0011).

149 *Insert figure 2*

150 **Figure 2 – Comparison between 2021 WUENIC-reported DTP3 coverage and expectations derived from historical trends:** This
151 scatterplot shows country coverage (WUENIC-reported actuals and ARIMA-predicted expectations) as dots. Lines around
152 individual points illustrate the 95% CIs of ARIMA predictions. Countries showing significant departure from expected values, i.e.,
153 for which actual coverage is outside the 95% CI of predictions, are indicated in red; countries without such significant departure
154 from expected results are shown in black.

155 Our analysis indicates an average global decline in DTP3 coverage of 3.6% (95%_{CI}: [2.6%; 4.6%]), from an
156 expected 90.1% to a reported 86.5% across 164 reporting countries. Global average coverage in 2021 for
157 this set of countries was last reported in 2005, continuing to validate our previously reported results
158 that the pandemic is associated with a 16-year setback in performance of immunisation programmes
159 globally. Similar trends were observed for DTP1 (global decline of 2.8%; 95%_{CI}: [2.0%; 3.6%] from an
160 expected 93.7% to a reported 90.9%), and for MCV1 (global decline of 3.8%; 95%_{CI}: [4.8%; 2.7%]) in

161 2021. Full results by country and vaccine dose can be seen in the Appendix (Sections S5, S6, and
162 Supplementary Tables). Sensitivity analyses also showed similar results (Appendix, Section S7).
163 Reported 2021 coverage represents a continued 0.8% decline from 2020 reported levels (DTP3: 87.3% in
164 2020 and 86.5% in 2021). Given the inclusion of historical updates to prior year coverage estimates for
165 some countries, we re-evaluated our previously published analysis of 2020 coverage declines (we also
166 updated inclusion and exclusion criteria, for consistency). Our re-analysis aligned with our previously
167 reported results – DTP3 global decline of coverage of 2.7% (95%_{CI}: [1.9%; 3.5%]), from an expected
168 90.0% to a reported 87.3%. Reproduced results are in the Appendix (Section S8).

169 *Insert figure 3*

170 **Figure 3 – Differences between expected and reported DTP3 vaccine coverage in 2021 across (A) UN regions and (B) income**
171 **groups.** Points represent individual countries, grouped, and coloured according to (A) UN region classification and (B) World
172 Bank income groups. Country coordinates on the X-axis were jittered for visibility. Values on the y-axis are indicated as absolute
173 differences between reported and expected vaccine coverage, in percentages. Violin plots show the density of the data within
174 each group: wider lines indicate more datapoints. The black dashed horizontal lines indicate no change in coverage. LIC: Low-
175 income Country. LMIC: Lower-middle-income Country. UMIC: Upper-middle-income Country. HIC: High-income Country.

176 At a regional level, there was evidence that coverage declined compared to previous trends in Africa,
177 the Americas and Asia and that coverage in the Americas declined furthest (Americas: 6.7% decline,
178 95%_{CI}: [4.8%; 9.3%]). Similar trends were seen across all vaccines modelled.

179 All income groups except for high-income countries exhibited statistical evidence of declines in coverage
180 at the 95% confidence level in 2021 for DTP1, DTP3, and MCV1, with the great divergence in expected
181 versus reported coverage consistently seen in lower-middle income countries (DTP3 LMICs; 5.5%, 95%_{CI}:
182 [3.6%; 7.3%]).

183 Heterogeneities due to one variable (regions or income groups) remained after accounting for the effect
184 of the other one (regional after accounting for differences in income group: for DTP3, ANOVA – $F = 5.22$,
185 $df = 156$, $p < 5.63 \times 10^{-4}$; income group after accounting for differences in regions: ANOVA – $F = 5.75$, df
186 $= 156$, $p < 9.33 \times 10^{-4}$). Evidence of heterogeneities remaining after accounting for order effects were
187 also seen for DTP1 ($p = 0.018$ for region after income, and $p = 2.68 \times 10^{-4}$ for income after region) and
188 MCV1 ($p = 0.003$ for both ANOVAs).

189 Additional missed immunisations and Zero Dose children in 2021

190 Zero Dose children are estimated using DTP1 data. These results on 168 countries for DTP1 represent
191 93% of the global surviving infant population in 2021. Based on point estimates of the total infant
192 populations across these countries, there were 1.61 million (M) Zero Dose children in 2021, of which
193 504.9 k (31.4%) were associated with unexpected coverage declines in 2021. This point estimate is
194 higher than the estimated additional 1.51 M ZD children in 2020, of which 358.3 k (23.8%) were
195 associated with coverage declines in 2020 vs. prior trends.

196 **Table 1** details the number of missed immunisations for the 10 countries with the absolute number of
197 additional missed immunisations compared to expectations for 2020 and 2021 combined. Of note, these
198 countries are all in Asia, Africa, or the Americas. This list of countries is very similar to the list of
199 countries with largest increases in missed immunisations in 2021 alone.

200

201 **Table 1.** Estimated DTP3 coverage declines and missed immunisations for 10 countries with most additional missed
202 immunisations total during 2020 and 2021. Bold rows indicate that WUENIC-reported coverage for each year is outside of the
203 forecast 95% CIs.

204 *Insert Table 1*

205 Year-on-year trends in point estimates of coverage

206 Absolute reported coverage indicates the proportion of children immunised in a given year per country,
207 and can be compared to previous coverage levels to understand if more or less children are being
208 reached each year. In terms of absolute reported coverage from 2019 to 2021, for DTP3, 40 countries
209 (24.4%) reported continued coverage declines for both consecutive years whereas just six countries
210 (3.7%) reported sustained coverage improvements year-on-year. The majority of countries either
211 exhibited coverage stagnation (39 countries, 23.8%) or a decline follow-up by stagnation (or stagnation
212 followed by a decline) - 24 countries (14.6%). The remaining 48 countries (29.3%) had coverage oscillate
213 (e.g., lower then higher, or higher then lower) over years. **Table 2** for a full breakdown for DTP3; similar
214 trends were seen for DTP1 and MCV1.

215 **Table 2.** Tabulation of number of countries by absolute year-on-year coverage trends for DTP3. Percentages show percent of all
216 164 included countries.

217 *Insert table 2*

218 At a country level the year-on-year reported changes in coverage can be seen in **Figure 4**, with Panel A
219 providing colour-coding by region and panel B by income group. Only six countries are in the top right
220 segment (consistent year-on-year coverage improvement for DTP3 during the first two years of the
221 pandemic) and all other countries reported some declines and/or static coverage levels during the
222 pandemic.

223 *Insert figure 4*

224 **Figure 4 – Year-on-year DTP3 trends: Comparison between 2021 WUENIC-reported DTP3 coverage and expectations derived**
225 **from historical trends.** Scatterplots A and B show the difference between 2020 and 2019 WUENIC-reported coverage on the x-
226 axis, and 2021 and 2020 WUENIC-reported coverage on the y-axis, categories by region (A) and income group (B) respectively.
227 Countries in the top-right corner increased coverage on both sequential years, whilst countries in the bottom-left countries
228 reported year-on-year declines. Scatterplot C shows the difference between forecasted and reported coverage in 2020 on the
229 x-axis and in 2021 on the y-axis. Countries in the top-right corner reported higher coverage than expected for both years, whilst

230 countries in the bottom-left corner reported lower coverage than expected for both years. Colour-coding indicates whether
231 reported coverage was within CIs of modelled projections or not. All figures show percentage point differences.

232 Year-on-year trends compared to forecasts

233 Comparing reported coverage to forecasted levels provides an indication of whether, and to what
234 extent, coverage deviated from country-specific previous trends during each year of the pandemic. For
235 the majority of countries (118, 72.0%) reported coverage fell within 95% CI forecasts for both 2020 and
236 2021. No countries had higher coverage in 2021 than forecasted confidence intervals, however 24
237 countries (14.6%) had lower coverage than expected in both years. A Fisher's Exact test confirmed that
238 trends observed in 2020 and in 2021 were correlated (DTP3: $p < 2 \times 10^{-13}$), largely due to an excess of
239 countries exhibiting declines in 2020 which continued in 2021 (**Table 3**)

240 **Table 3.** Tabulation of number of countries comparing reported vs. expected coverage in 2020 and 2021 for DTP3. Percentages
241 show percent of all countries.

242 *Insert Table 3*

243 **Discussion**

244 Global routine immunisation continues decline

245 Our results suggest that the global decline in RI coverage observed in 2020 has continued in 2021. In
246 contrast with previous indications in the latter half of 2020 that services and coverage was returning to
247 pre-pandemic levels [22], we found virtually no indication of rebounds in RI coverage, and many
248 instances of countries where decline continued further in 2021 ($n = 40$, 24.4% of countries), where
249 declines occurred following stagnation in the first year of the pandemic ($n = 11$, 6.7% of countries), or
250 coverage continues to stagnate at 2019 levels ($n = 39$, 23.8% of countries). Immunisation performance
251 has not reverted to pre-pandemic levels during the continuation of the pandemic and has instead
252 declined further from the previously achieved improvement trajectory. Global WUENIC-reported

253 coverage across the 164 included countries for DTP3 declined continuously from 89.8% in 2019 to 87.3%
254 in 2020 to 86.5% in 2021. This compares to an expected 90.1% coverage in 2021 (i.e., decline of 3.6%,
255 95%_{CI}: [2.6%; 4.6%]). See **Figure 5** for an overview of DTP1, DTP3, and MCV1 coverage actuals and
256 expectations from 2000 to 2021.

257 *Insert figure 5*

258 **Figure 5 – Global DTP1, DTP3, and MCV1 coverage.** Line graph shows DTP1 coverage in red, DTP3 coverage in green, and MCV1
259 coverage in blue from 2000-2021 inclusive. Filled lines show reported WUENIC coverage and dotted lines from 2019-2021 show
260 expected trends based on ARIMA modelling of prior coverage.

261 Between 2019 and 2021, two-thirds of countries exhibited either continuous declines year-on-year, or
262 declines followed by stagnation (or vice versa) during the pandemic. These findings confirm qualitative
263 reports from the World Health Organisation (WHO) that immunisation services have been continuously
264 interrupted throughout the pandemic (56% of countries reported disruptions in Q3 2020, 42% in Q1
265 2021, and 53% in Q4 2021 [23]).

266 The trend in declines in RI coverage during the pandemic period is largest in the Americas, Africa, and
267 Asia; and for low- and middle-income countries (with region and income group both having independent
268 explanatory power). This trend is also consistent across vaccines, delivered at different schedules (DTP1
269 typically delivered at 6-weeks, DTP3 at 14-weeks, and MCV1 at 9-months old).

270 Our results cover over 90% of the surviving infant population in 2021 – over 119 M infants. However,
271 our results are limited to annual trends reported at a national level. Publicly available data on globally
272 recognised estimates of coverage at a monthly level would enable more granular time series modelling
273 on the impact of the pandemic on RI, ideally with shorter time lags between events and reporting.

274 Missed immunisations

275 The compounded impact of two years with RI coverage at lower levels (or coverage declines then
276 stagnation or vice versa) in many countries will place an increasing toll on RI vaccine requirements and
277 increase complexity of service delivery. In 2023, there will be an increasing number of unvaccinated one-
278 and two-year-olds in many countries. Vaccine programmes typically plan vaccine supply requirements
279 and procurement based on surviving infant populations. This approach may need to evolve to actively
280 include quantification of missed immunisation in older populations to ensure sufficient vaccines for
281 catch-up through RI touchpoints. Furthermore, reaching children over one-years old is not “typical” (in
282 most countries) for RI, and infants of this age do not necessarily routinely engage with the health system
283 at appropriate times and places to be reached through ad-hoc catch-up. Resultingly, catch-up campaigns
284 – targeted at sub-populations where coverage has declined the most – may be required. More data and
285 research at the sub-national level is required in order to determine the most appropriate catch-up
286 routes and supplementary immunisation activities (SIAs). WUENIC data is published at national level,
287 therefore alternative coverage data sources, e.g., administration data (which has some known caveats –
288 see Appendix Section S1) or other sub-national level surveys would be required.

289 Zero Dose

290 Notably, the number of Zero Dose children also continued to grow: DTP1 coverage across the modelled
291 countries fell from a reported 91.6% to 90.9% between 2020 and 2021, compared to an expected 93.7%
292 coverage in 2021 (i.e., decline of 2.8%, 95%_{CI}: [2.0%; 3.6%]) - see **Figure 5** for visual depiction. This
293 translates to an additional 3.4 million Zero Dose children on top of an expected 11.0 million (30.9%
294 increase). These figures for both 2020 and 2021 are updated using the most recent UN WPP estimates,
295 based on the medium variant surviving infant population estimates. Population estimates, particularly in
296 fragile states where a national census may not have been conducted for years or decades, are known to
297 sometimes have wide confidence intervals (see UN WPP 2022 projections) - therefore the number of
298 Zero Dose children could be larger still.

299 The decline in DTP1 coverage was 77% of the size of the decline in DTP3 coverage (2.8% vs. 3.6%). This
300 suggests that of the additional 4.3 M infants not receiving DTP3 globally in 2021 associated with
301 pandemic declines, 3.3 M of these were additional Zero Dose children versus expectations, and 1 M
302 resulted from increased drop out between vaccine doses. On the one hand, this is particularly
303 concerning given the tight linkage between Zero Dose children and adverse health outcomes (e.g.,
304 disease outbreaks and vaccine preventable deaths). However, recognition that declines in coverage
305 appear to be primarily driven by increases in ZD, rather than greater dropout between vaccine doses,
306 provide insights on where to target limited resources for catch-up on health system strengthening. This
307 places heightened importance on the increasing focus on channeling resources to identify and reach
308 Zero Dose children.

309 Additionally, several individual countries with large birth cohorts reported coverage below the expected
310 95% CIs, indicating strong evidence in large increases in Zero Dose children during the continued
311 pandemic. These countries include: India, Indonesia, Philippines and Mozambique (see **Table 1** above) -
312 and these could be important focus countries for health system strengthening support.

313 Vaccine preventable disease outbreaks

314 The large decline in Measles coverage (MCV1 global decline of 3.8%; 95%_{CI}: [4.8%; 2.7%]) is particularly
315 concerning given the high sustained coverage (95%) required to prevent measles outbreaks [24]. Global
316 disease surveillance suggests that this – along with other factors including delays to measles campaign
317 implementation, potentially also pandemic related – are translating into an increase in worldwide
318 measles outbreaks [25]. Recent modelling has modelled the link between declines in immunisation
319 coverage and vaccine-preventable disease outbreaks based on scenarios of uniform declines in coverage
320 [26] - such methods could be enhanced to build on our country-specific modelled declines in coverage
321 to more precisely estimate potential increases in vaccine-preventable diseases. This could help

322 proactively target campaigns where outbreaks would be most likely to occur, if real time coverage
323 declines are identified.

324 Factors for pandemic resilience

325 Whilst income group and regional factors (independently) explain some of the global declines in
326 coverage (adjusted $R^2 = 0.14$ for the linear model including income group and region), further
327 understanding of explanatory factors is required to guide recovery and build resilience globally for
328 future pandemics. Understanding the impact of Non-Pharmaceutical Interventions (NPIs) and COVID-19
329 rollout on health service access and delivery may be valuable starting points. Countries deployed a wide
330 variety of NPIs over time, which influenced mobility and societal behaviours [27], and influenced
331 immunisation services [28]. These interventions have been captured and codified in global datasets,
332 such as the COVID-19 Government Response Tracker [29]. Exploring the relationship between NPI
333 implementation and immunisation system performance over the last two years may indicate policy
334 areas with beneficial and deleterious effects on health systems. Additionally, approximately 50% of
335 countries surveyed by the WHO reported direct trade-offs between COVID-19 vaccination programme
336 rollout and RI service delivery for infants and school-aged children [23]. Further quantification of the
337 trade-off between continued COVID-19 vaccination efforts and RI, in terms of morbidity and mortality
338 implications, could be valuable in guiding immunisation strategies at the country- and global- level in the
339 coming years (as efforts to integrate COVID-19 in immunisation programmes continue).

340 Finally, a select few examples of countries achieving coverage improvements year-on-year and/or
341 reported coverage higher than forecasts in 2020, despite the backdrop of the pandemic. These countries
342 may provide case studies to explore for translational learnings. For example, Chad's reported DTP3
343 coverage increased from 50% in 2019 to 52% in 2020 and 58% in 2021 (although it is noted that

344 coverage was within 95% forecasted CIs for both years); and Namibia's 2020 reported DTP3 coverage of
345 93% was higher than forecasted (point estimate: 87% (95%_{CI}: [81·4%; 92·6%]).

346

347 **Conclusion**

348 This research builds on our previously published, transparent, and replicable approach for estimating
349 gaps in RI coverage across countries, providing an objective measure for missed immunisations and
350 coverage disruptions in 2021. It is clear that immunisation services continued to be disrupted in many
351 low- and middle-income countries, particularly in the Americas, Africa, and Asia, and we hope this work
352 can inform future research to identify effective interventions to facilitate rebounds in coverage to
353 previous levels and catch-up of growing populations of under- and un-immunised children.

354

355 **Acknowledgements**

356 TJ acknowledges funding from the MRC Centre for Global Infectious Disease Analysis (reference
357 MR/R015600/1), jointly funded by the UK Medical Research Council (MRC) and the UK Foreign,
358 Commonwealth & Development Office (FCDO), under the MRC/FCDO Concordat agreement and is also
359 part of the EDCTP2 programme supported by the European Union. OK was funded by the Swiss National
360 Science Foundation (grant number PP00P3_202660). These funders had no role in the design and
361 conduct of this study; collection, management, analysis, and interpretation of the data; preparation,
362 review, or approval of the manuscript; and decision to submit the manuscript for publication.

363 BE is a PhD student at the Institute of Global Health, Faculty of Medicine, University of Geneva and
364 received no funding.

365

366 **Conflict of interest**

367 The authors declare the following financial interests/personal relationships which may be considered as
368 potential competing interests: It is noted that BE has been employed by the Clinton Health Access
369 Initiative in the Global Vaccines team in the last three years; and is currently employed by Gavi. All
370 research contained in this manuscript was conducted during a doctorate qualification, outside and
371 independent of employment. Neither facilities, data, nor any other forms of input from the Clinton
372 Health Access Initiative or Gavi, were used in this study. The research and manuscript are independent
373 of the Clinton Health Access Initiative and Gavi, and the findings have not been discussed, reviewed, or
374 endorsed by the Clinton Health Access Initiative, the Gavi Secretariat, or any Alliance members.

375

376 **References**

- 377 [1] SeyedAlinaghi SA, Karimi A, Mojdeganlou H, Alilou S, Mirghaderi SP, Noori T, et al. Impact of
378 COVID-19 pandemic on routine vaccination coverage of children and adolescents: A systematic
379 review. *Health Sci Rep* 2022;5:e00516. <https://doi.org/10.1002/HSR2.516>.
- 380 [2] Chiappini E, Parigi S, Galli L, Licari A, Brambilla I, Angela Tosca M, et al. Impact that the COVID-19
381 pandemic on routine childhood vaccinations and challenges ahead: A narrative review. *Acta
382 Paediatr* 2021;110:2529–35. <https://doi.org/10.1111/APA.15949>.
- 383 [3] Yunusa Id A, Cabral Id C, Id EA. The impact of the Covid-19 pandemic on the uptake of routine
384 maternal and infant vaccines globally: A systematic review. *PLOS Global Public Health*
385 2022;2:e0000628. <https://doi.org/10.1371/JOURNAL.PGPH.0000628>.
- 386 [4] Dinleyici EC, Borrow R, Safadi MAP, van Damme P, Munoz FM. Vaccines and routine
387 immunization strategies during the COVID-19 pandemic.

- 388 <https://doi.org/10.1080/2164551520201804776> 2020;17:400–7.
- 389 <https://doi.org/10.1080/21645515.2020.1804776>.
- 390 [5] Muhoza P, Danovaro-Holliday MC, Diallo MS, Murphy P, Sodha S v., Requejo JH, et al. Routine
391 Vaccination Coverage — Worldwide, 2020. Morbidity and Mortality Weekly Report
392 2021;70:1495. <https://doi.org/10.15585/MMWR.MM7043A1>.
- 393 [6] Causey K, Fullman N, Sorensen RJD, Galles NC, Zheng P, Aravkin A, et al. Estimating global and
394 regional disruptions to routine childhood vaccine coverage during the COVID-19 pandemic in
395 2020: a modelling study. Lancet 2021;398:522–34. [https://doi.org/10.1016/S0140-
396 6736\(21\)01337-4](https://doi.org/10.1016/S0140-6736(21)01337-4).
- 397 [7] Evans B, Jombart T. Worldwide routine immunisation coverage regressed during the first year of
398 the COVID-19 pandemic. Vaccine 2022;40:3531–5.
399 <https://doi.org/10.1016/J.VACCINE.2022.01.044>.
- 400 [8] Kostandova N, Loiate S, Winter A, Moss WJ, Giles JR, Metcalf CJE, et al. Impact of disruptions to
401 routine vaccination programs, quantifying burden of measles, and mapping targeted
402 supplementary immunization activities. Epidemics 2022;41:100647.
403 <https://doi.org/10.1016/J.EPIDEM.2022.100647>.
- 404 [9] Zucker JR, Rosen JB, Iwamoto M, Arciuolo RJ, Langdon-Embry M, Vora NM, et al. Consequences
405 of Undervaccination — Measles Outbreak, New York City, 2018–2019. New England Journal of
406 Medicine 2020;382:1009–17.
407 https://doi.org/10.1056/NEJMOA1912514/SUPPL_FILE/NEJMOA1912514_DISCLOSURES.PDF.
- 408 [10] Alves L. Declining immunisation coverage in Brazil. Lancet Infect Dis 2022;22:596.
409 [https://doi.org/10.1016/S1473-3099\(22\)00238-9](https://doi.org/10.1016/S1473-3099(22)00238-9).


- 410 [11] Immunization coverage n.d. [https://www.who.int/news-room/fact-sheets/detail/immunization-](https://www.who.int/news-room/fact-sheets/detail/immunization-coverage)
411 [coverage](https://www.who.int/news-room/fact-sheets/detail/immunization-coverage) (accessed November 20, 2022).
- 412 [12] Rachlin A, Danovaro-Holliday MC, Murphy P, Sodha S v., Wallace AS. Routine Vaccination
413 Coverage — Worldwide, 2021. MMWR Morb Mortal Wkly Rep 2022;71:1396–400.
414 <https://doi.org/10.15585/MMWR.MM7144A2>.
- 415 [13] Zero-dose children and missed communities n.d. [https://www.gavi.org/our-](https://www.gavi.org/our-alliance/strategy/phase-5-2021-2025/equity-goal/zero-dose-children-missed-communities)
416 [alliance/strategy/phase-5-2021-2025/equity-goal/zero-dose-children-missed-communities](https://www.gavi.org/our-alliance/strategy/phase-5-2021-2025/equity-goal/zero-dose-children-missed-communities)
417 (accessed November 20, 2022).
- 418 [14] Burton A, Kowalski R, Gacic-Dobo M, Karimov R, Brown D. A Formal Representation of the WHO
419 and UNICEF Estimates of National Immunization Coverage: A Computational Logic Approach.
420 PLoS One 2012;7:e47806. <https://doi.org/10.1371/JOURNAL.PONE.0047806>.
- 421 [15] Burton A, Monasch R, Lautenbach B, Gacic-Dobo M, Neill M, Karimov R, et al. WHO and UNICEF
422 estimates of national infant immunization coverage: methods and processes. Bull World Health
423 Organ 2009;87:535–41. <https://doi.org/10.2471/BLT.08.053819>.
- 424 [16] WHO/UNICEF Immunization Coverage Estimates - 2021 revision n.d.
425 https://www.who.int/publications/m/item/WUENIC_notes (accessed November 20, 2022).
- 426 [17] United Nations D of E and SAPD. World Population Prospects 2022 Data Sources 2022.
- 427 [18] World Bank Country and Lending Groups – World Bank Data Help Desk n.d.
428 [https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-](https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups)
429 [lending-groups](https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups) (accessed November 23, 2022).
- 430 [19] Hyndman RJ, Khandakar Y. Automatic Time Series Forecasting: The forecast Package for R. J Stat
431 Softw 2008;27:1–22. <https://doi.org/10.18637/JSS.V027.I03>.

- 432 [20] R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: 2021.
- 433 [21] bevans249/modelling_covid_impact_RI: Code for modelling impact of pandemic in 2020 and
434 2021 on Routine Immunisation (RI) globally. n.d.
435 https://github.com/bevans249/modelling_covid_impact_RI (accessed November 20, 2022).
- 436 [22] Shet A, Carr K, Danovaro-Holliday MC, Sodha S v., Prospero C, Wunderlich J, et al. Impact of the
437 SARS-CoV-2 pandemic on routine immunisation services: evidence of disruption and recovery
438 from 170 countries and territories. *Lancet Glob Health* 2022;10:e186–94.
439 [https://doi.org/10.1016/S2214-109X\(21\)00512-X](https://doi.org/10.1016/S2214-109X(21)00512-X).
- 440 [23] Third round of the global pulse survey on continuity of essential health services during the
441 COVID-19 pandemic n.d. [https://www.who.int/publications/i/item/WHO-2019-nCoV-](https://www.who.int/publications/i/item/WHO-2019-nCoV-EHS_continuity-survey-2022.1)
442 [EHS_continuity-survey-2022.1](https://www.who.int/publications/i/item/WHO-2019-nCoV-EHS_continuity-survey-2022.1) (accessed November 22, 2022).
- 443 [24] Bedford H, Donovan H. We need to increase MMR vaccine uptake urgently. *BMJ* 2022;376.
444 <https://doi.org/10.1136/BMJ.O818>.
- 445 [25] Measles cases are spiking globally | UNICEF n.d. [https://www.unicef.org/stories/measles-cases-](https://www.unicef.org/stories/measles-cases-spiking-globally)
446 [spiking-globally](https://www.unicef.org/stories/measles-cases-spiking-globally) (accessed November 20, 2022).
- 447 [26] Toor J, Li X, Jit M, Trotter CL, Echeverria-Londono S, Hartner AM, et al. COVID-19 impact on
448 routine immunisations for vaccine-preventable diseases: Projecting the effect of different routes
449 to recovery. *Vaccine* 2022;40:4142–9. <https://doi.org/10.1016/J.VACCINE.2022.05.074>.
- 450 [27] Perra N. Non-pharmaceutical interventions during the COVID-19 pandemic: A review. *Phys Rep*
451 2021;913:1–52. <https://doi.org/10.1016/J.PHYSREP.2021.02.001>.
- 452 [28] Nelson R. COVID-19 disrupts vaccine delivery. *Lancet Infect Dis* 2020;20:546.
453 [https://doi.org/10.1016/S1473-3099\(20\)30304-2](https://doi.org/10.1016/S1473-3099(20)30304-2).

454 [29] Hale T, Angrist N, Goldszmidt R, Kira B, Petherick A, Phillips T, et al. A global panel database of
455 pandemic policies (Oxford COVID-19 Government Response Tracker). Nat Hum Behav
456 2021;5:529–38. <https://doi.org/10.1038/S41562-021-01079-8>.

457

458



Actual coverage in 2021

100 %
80 %
60 %
40 %


25 %



50 %

75 %

100 %

Expected coverage in 2021





A


Region ● Africa ● Americas ● Asia ● Europe ● Oceania

Difference between coverage in 2021 vs. 2020 (percentage points)

**B**


Income group ● LIC ● LMIC ● UMIC ● HIC


Difference between coverage in 2021 vs. 2020 (percentage points)

**C**

Confidence in coverage changes ● Within CIs ● 1 of 2 years outside CI ● Outside CIs

Difference between forecast and reported coverage (2021)





Country	UN region	Income group	ARIMA modelled expected 2021 coverage [95% CI]	WUENIC reported 2021 coverage	ARIMA modelled expected 2020 coverage [95% CI]	WUENIC reported 2020 coverage	Total missed immunisations (2020 + 2021)	Additional missed immunisations (2020)	Additional missed immunisations (2021)	Proportion ¹
India	Asia	LMIC	96.1% [92.2%; 99.0%]	88.0%	95.1% [92.3%; 97.8%]	87.0%	5,647,825	1,819,194	1,831,084	64.6%
Indonesia	Asia	LMIC	90.0% [83.7%; 96.3%]	74.0%	90.0% [85.5%; 94.5%]	83.0%	1,901,566	309,557	707,559	53.5%
Pakistan	Asia	LMIC	92.2% [84.6%; 99.0%]	90.0%	91.1% [85.7%; 96.5%]	83.0%	1,648,523	494,878	134,966	38.2%
Ethiopia	Africa	LIC	79.1% [70.2%; 87.9%]	70.0%	77.5% [71.3%; 83.8%]	76.0%	2,041,527	57,703	342,244	19.7%
Democratic Republic of the Congo	Africa	LIC	87.7% [74.8%; 99.0%]	81.0%	85.8% [76.7%; 94.9%]	83.0%	1,391,281	109,837	258,322	26.5%
Philippines	Asia	LMIC	73.0% [63.0%; 83.0%]	57.0%	73.0% [65.9%; 80.1%]	74.0%	1,681,668	-24,372	389,952	21.4%
Mozambique	Africa	LIC	91.0% [87.2%; 94.8%]	67.0%	91.0% [89.0%; 93.0%]	83.0%	562,900	90,063	270,191	64.9%
United Republic of Tanzania	Africa	LMIC	92.8% [86.3%; 99.0%]	82.0%	92.1% [86.6%; 97.5%]	88.0%	670,622	90,979	241,045	49.5%
Angola	Africa	LMIC	67.0% [51.1%; 82.9%]	57.0%	67.0% [55.7%; 78.3%]	61.0%	1,055,148	77,205	128,676	19.6%
Mexico	Americas	UMIC	84.0% [75.0%; 93.0%]	83.0%	84.0% [77.7%; 90.3%]	77.0%	745,482	130,459	18,637	20.7%

1 Proportion of total missed immunisations associated with coverage declines in both 2020 and 2021 compared to prior year trends

		2021 coverage vs. 2020 coverage		
		Lower	Static	Higher
2020 coverage vs. 2019 coverage	Lower	40 (24.4%)	13 (7.9%)	36 (22.0%)
	Static	11 (6.7%)	39 (23.8%)	4 (2.4%)
	Higher	12 (7.3%)	3 (1.8%)	6 (3.7%)

		2021 reported coverage vs. expectations		
2020 reported coverage vs. expectations		Lower	Within CIs	Higher
	Lower	24 (14.6%)	6 (3.7%)	0 (0%)
	Within CIs	15 (9.1%)	118 (72.0%)	0 (0%)
	Higher	0 (0%)	1 (0.6%)	0 (0%)